PURPOSE: Endocan is a proteoglycan expressed by endothelial cells in the lung that may inhibit leukocyte recruitment and thus prevent the development of acute lung injury (ALI). We tested the association of serum endocan levels with subsequent development of ALI after major trauma. MATERIALS AND METHODS: This was a single-center nested case-control study within a prospective cohort study of major trauma patients. Using an enzyme-linked immunosorbent assay test, we measured endocan levels from admission serum in 24 controls (no ALI) and 24 cases (ALI within 5 days of trauma). Multivariable logistic regression was used to test the association of admission serum endocan levels with subsequent ALI. RESULTS: Patients who developed ALI had lower levels of endocan on admission (mean, 3.5 ± 1.4 ng/mL vs 4.9 ± 2.6 ng/mL in controls; P = .02). For each 1-unit increase in serum endocan level, the odds ratio for ALI development decreased (0.69; 95% confidence interval, 0.49-0.97; P = .03). Lower endocan levels remained associated with a higher incidence of ALI after adjustment for age and illness severity. CONCLUSIONS: Lower levels of serum endocan on admission are associated with subsequent development of ALI in trauma patients. These observations may be explained by endocan-mediated blockade of leukocyte recruitment in the lung.
PURPOSE:Endocan is a proteoglycan expressed by endothelial cells in the lung that may inhibit leukocyte recruitment and thus prevent the development of acute lung injury (ALI). We tested the association of serum endocan levels with subsequent development of ALI after major trauma. MATERIALS AND METHODS: This was a single-center nested case-control study within a prospective cohort study of major traumapatients. Using an enzyme-linked immunosorbent assay test, we measured endocan levels from admission serum in 24 controls (no ALI) and 24 cases (ALI within 5 days of trauma). Multivariable logistic regression was used to test the association of admission serum endocan levels with subsequent ALI. RESULTS:Patients who developed ALI had lower levels of endocan on admission (mean, 3.5 ± 1.4 ng/mL vs 4.9 ± 2.6 ng/mL in controls; P = .02). For each 1-unit increase in serum endocan level, the odds ratio for ALI development decreased (0.69; 95% confidence interval, 0.49-0.97; P = .03). Lower endocan levels remained associated with a higher incidence of ALI after adjustment for age and illness severity. CONCLUSIONS: Lower levels of serum endocan on admission are associated with subsequent development of ALI in traumapatients. These observations may be explained by endocan-mediated blockade of leukocyte recruitment in the lung.
Authors: Giora Netzer; Chirag V Shah; Theodore J Iwashyna; Paul N Lanken; Barbara Finkel; Barry Fuchs; Wensheng Guo; Jason D Christie Journal: Chest Date: 2007-05-15 Impact factor: 9.410
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Samina Yasmin Khan; Marguerite R Kelher; Joanna M Heal; Neil Blumberg; Lynn K Boshkov; Richard Phipps; Kelly F Gettings; Nathan J McLaughlin; Christopher C Silliman Journal: Blood Date: 2006-06-13 Impact factor: 22.113
Authors: Ognjen Gajic; Fernando Frutos-Vivar; André Esteban; Rolf D Hubmayr; Antonio Anzueto Journal: Intensive Care Med Date: 2005-04-26 Impact factor: 17.440
Authors: Michelle Ng Gong; B Taylor Thompson; Paige Williams; Lucille Pothier; Paul D Boyce; David C Christiani Journal: Crit Care Med Date: 2005-06 Impact factor: 7.598
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Xiaoyi Zheng; Fariborz Soroush; Jin Long; Evan T Hall; Puneeth K Adishesha; Sanchita Bhattacharya; Mohammad F Kiani; Vivek Bhalla Journal: PLoS One Date: 2017-09-21 Impact factor: 3.240